VA-REGULA
Regula 70X9 document readers were shipped to three Uber Verification Centers in Warsaw, Krakow, and Poznan, which serve as dedicated hubs where drivers submit their driver’s licenses and identification documents for thorough verification. The shipment was fulfilled by Regula’s Polish distributor, Korporacja Wschód (KW), whose forensic experts also provided special training on how to use the new devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430896042/en/
Regula document readers power the driver verification process for Uber Poland (Photo: Business Wire)
The Regula 70X9 became the core element of Uber’s mission to enhance their safety protocols. It allows Uber employees to perform a comprehensive set of checks to authenticate an ID. The reader automatically identifies the document type; reads the data in all the document zones, including the visual zone, MRZ (machine-readable zone), RFID (radio frequency identification) chips, and barcodes; and cross-compares the obtained text and graphic data. Plus, the supplied document readers are equipped with Automatic Authenticity Control technology. At its core are automated checks that swiftly assess the integrity of the provided documents, detecting any signs of forgery or alteration. All of the above features, together with integrated light sources, significantly reduce the risk of mistakenly verifying forged documents.
The current workflow carried out by Uber’s employees includes:
Step 1. Comparison of the documents provided by the driver with the documents uploaded in the Uber application.
Step 2. Verification of Background Check Certificate.
Step 3. Authenticity verification of passport/ID and driver’s license with the Regula 70X9 reader.
Step 4. Taking a driver’s profile picture.
Step 5. Finalizing verification in the system: data input, document upload, and profile picture upload.
“The process of personally vetting drivers has been, and continues to be, a major logistical challenge, but we believe our efforts will help improve safety in transit. Thanks to the Regula device, the first stage went very smoothly for us. This process, although lengthy, is certainly effective,” says Marcin Konrad Moczyrog, Director and Global Manager at Uber Rides, Central & Eastern Europe.
Prior to the integration of the Regula 70X9, drivers’ documents were verified by Uber’s employees, either manually or via an application based on AI algorithms. The old method had two problems: it was time-consuming, and it did not guarantee protection against high-level forgeries of documents.
“Document fraud is constantly on the rise, and since counterfeited documents are becoming more sophisticated, manual checks are no longer enough. Some inherent document security features may be verified only with special equipment or software solutions. We are honored that our devices have become the cornerstone for a revamped verification process at Uber, and are pleased to see that it’s bearing fruit,” says Maris Kaminskis, Executive Director at Regula Europe.
For additional information, please visit the website.
About Uber
Uber is a technology application connecting passengers and drivers that has revolutionized the way people travel. Since its inception in 2009, Uber has experienced exponential growth, expanding its operations to numerous cities worldwide. Uber operates in more than 10,000 cities across more than 71 countries, making it one of the largest ride-hailing platforms globally.
In Poland, Uber is available in 25 locations.
About Korporacja Wschód
Founded in 1995, Korporacja Wschód is a family-run business that has continually evolved to meet the dynamic needs of high-technology sectors. As the distributor of Regula products in Poland since 1996, we have established ourselves as a vital link in delivering technological solutions to various enforcement and security agencies. Our expertise spans the development, integration, implementation, and distribution of advanced technology equipment, catering primarily to Border Guards, Police, Military, and a range of non-governmental enterprises and institutions. Our collaboration with Regula, a leader in forensic science technologies, underscores our commitment to offering cutting-edge solutions in document verification and security.
Learn more at https://korporacjawschod.pl.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240430896042/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
